Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Core Insights - Neurocrine Biosciences has initiated a Phase 1 clinical study for NBI-1140675, an investigational oral selective second-generation small molecule inhibitor of VMAT2, aimed at treating neurological and neuropsychiatric conditions [1][2] - The company aims to expand its portfolio of VMAT2 inhibitors, building on the success of valbenazine, which is approved for tardive dyskinesia and chorea associated with Huntington's disease [2] Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company focused on neuroscience, dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders [3] - The company has a diverse portfolio that includes FDA-approved treatments for various conditions and a robust pipeline with multiple compounds in mid- to late-phase clinical development [3]